Outcome of sustained virological responders with histologically advanced chronic hepatitis C. - Wikidata - awgldk - TriplyDB

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

http://www.wikidata.org/entity/Q34101701

about

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Management of HCV-Associated Liver Cirrhosis.Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Historical review of the causes of cancer Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective Emerging therapies for hepatitis C Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases Future classes of hepatitis C virus therapeutic agents Antiviral therapies for chronic hepatitis C virus infection with cirrhosis Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014 HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors HIV, Aging, and Viral Coinfections: Taking the Long View.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.Causal inference regarding infectious aetiology of chronic conditions: a systematic review.Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States Processes to manage analyses and publications in a phase III multicenter randomized clinical trial Hepatitis C in Argentina: epidemiology and treatment.Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.Hepatocellular carcinoma: early-stage management challenges Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965 Current and future therapies for hepatitis C virus infection.TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review).Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

P2860

Q24200197-316F840C-3B63-4E43-9677-C7E8AC9E640E Q24200534-D49F07DD-6C61-4BC3-AB56-67C1C043639A Q24632766-3FFC6DD9-DBB0-440E-AD0C-D0F459385C7E Q26740320-ABD94ECB-50C8-4458-BBC0-6129CF589673 Q26752433-52EF528F-A9EE-4DA5-B0F5-5DA6E267ADAE Q26767036-48881B99-9F76-49EC-AE9A-99128F3D78A8 Q26777659-93A85F9B-9EC7-4AED-97C2-4FF3C0BBEBD6 Q26795750-3AA3CCFA-9134-4E26-9507-03FE1EAF43A5 Q26820811-0A82D7D5-8B96-41C3-8291-D2A304D21894 Q26827517-639AFB08-6163-482D-832B-524C56C38675 Q26853642-CDDC3585-9799-4092-AD2A-0D92F2E8206D Q26863522-54770C37-A0FB-4172-BF55-AEF966E11C15 Q27009321-E743BFF2-B5D0-45ED-A2D7-893EFAE84EF5 Q27022794-C53949BF-D380-40C6-B33D-7B8DD811F6EE Q28076352-9910F722-005D-4B4D-863C-8729F19952BD Q28081137-9CB4067F-05CB-4F10-8FB0-66E275F92972 Q28481038-569FFC2D-3929-4635-A79B-0D16C221F7E6 Q30245486-FD76960F-F3A7-4200-8B2C-01C49D345C60 Q30250088-D5B82FF5-97E0-4B44-8673-24F1EFBB4146 Q30250322-73513920-3984-4BD4-AAD7-E3C050FF4CE0 Q30399476-5567A046-9359-4F8A-A14C-CCA54C03729E Q30459124-BEE64256-D799-46AA-89F8-3ACE90E446E7 Q31126057-6D4745C7-D764-4367-936D-CB7DAE5128F5 Q33400529-CD94B0CE-DEB1-48B6-B6A6-5087864FA5B4 Q33403491-32575490-046E-4ED3-B1AF-C60473B0B6A3 Q33413353-C02837E9-F260-471D-9B66-4D53CE3C4C1B Q33414605-14234A8F-B669-4572-BB2F-5FC37DCEE174 Q33424436-761894E8-29CE-457F-9A71-830DDC4C2DD8 Q33427048-B837A054-9327-4AB5-AFEE-87C0EEE46BCB Q33430833-9695F84F-C3DC-4FF0-8051-52B6FF43B014 Q33595820-36D92C52-DF82-42E3-B02A-B533BC300989 Q33694159-BBD9AE36-1912-4BAE-8038-DA0218BEDD37 Q33706886-F8D6847F-160A-44DA-AFC7-864EB0206C88 Q33723810-21FB3F59-C8A4-4C96-B24C-C1CDBD042219 Q33807745-B14C67D8-3CE7-4B5D-96A6-A8BF6C15907B Q33881131-A6EB06FD-B9F9-470F-9D8E-6DF748EC747D Q33929521-F6126736-BB4D-48F1-9473-6CC2C8224E1F Q34036762-7C9B37B2-D5C0-4E1C-879F-DD8D839A30E6 Q34120419-7BB7F02E-C43F-4E51-BA55-235B2AED85C8 Q34172595-F05F7CAD-96DD-4660-96A1-3C1582A7B886

P2860

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

http://www.wikidata.org/entity/Q34101701

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@ast

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@en

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@nl

type

label

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@ast

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@en

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@nl

prefLabel

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@ast

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@en

Outcome of sustained virologic ...... advanced chronic hepatitis C.

@nl

P1433

Q34101701-8ABC712D-585A-4A0F-A024-41388973ECA1

P1476

Q34101701-C1021B52-7A4D-455A-BCC1-AA43EAF412C3

P2093

Q34101701-1A6E2DB7-5270-4167-8289-0FE4B84F945B

Q34101701-1FBCBDC9-017E-4CBA-BAA2-5CA3C805522D

Q34101701-641467CB-DADF-48DE-9742-12AFAC5DB402

Q34101701-706A4A45-EE99-4CC9-A700-7C1D09814A0B

Q34101701-7E73A6AE-37A8-4BF1-80F1-231A577332E9

Q34101701-8DC6A96A-4BEE-4889-B813-1E14AA1A9E70

Q34101701-BB672335-CA0D-43A6-85AE-B184FF18BFDE

Q34101701-CE3CCEC8-D0E8-43FA-BD35-8C39D8E4C5EC

Q34101701-CF67E88D-4CC7-4209-9B11-C5355971B4F1

Q34101701-CF898CDA-451D-41EC-A8CC-04E20324C3D6

P2860

Q34101701-05EC4D2C-A24A-4940-8E59-B68DBC5ABE35

Q34101701-222B988A-5277-4424-B348-71B4419D5B11

Q34101701-29E6D132-C3F2-4C48-878E-6F0B19D1222C

Q34101701-3715D497-C8AD-48BF-A094-9404FED77427

Q34101701-3A90D076-AEB5-4190-9F79-B17FDB236B41

Q34101701-3E241BD1-BA84-4FB6-BD09-2D558BF2C536

Q34101701-4935130F-B4A3-4967-A7D7-098A947992AA

Q34101701-7F940314-BBCF-408D-9418-1589A70532B4

Q34101701-8915BD58-CF94-49CF-9283-DE1BDB6EFBAB

Q34101701-A48D2FF7-C5DE-4A40-997B-C434F2F2BE2C

P304

Q34101701-2206289F-EDE9-42A7-B582-29E07646E294

P31

Q34101701-B10DA84D-BBD8-4023-90D9-FC27F42F1AB1

P356

Q34101701-8FD1F9CF-CB8B-4D73-ABE4-EB45614D498D

P407

Q34101701-F441CFDE-D0D2-4788-AD95-C335E12508FD

P433

Q34101701-0DFD7E9C-BEF8-4A69-9B5A-EEAE697FFE32

P478

Q34101701-1DDE510E-9A66-4015-AF50-9C6D49C2C4C3

P50

Q34101701-5B29DB6B-9DF4-4D25-9D8B-DA9DF09E5D78

Q34101701-82914544-3766-47E6-89EE-227D8EA5A26F

P577

Q34101701-8B7560D3-F100-422C-8CC6-634DBF714A17

P5875

Q34101701-8ACA4D10-96FD-44F5-B732-16BA972B6FB5

P698

Q34101701-07CC814B-353C-4406-99F2-4780C75CC2D0

P921

Q34101701-D82C9188-62D8-4DD8-90A9-711F265FF385

P932

Q34101701-CC57547D-A5C1-46B3-8B73-8555AE63CA07

P356

P1433

P1476

Outcome of sustained virologic ...... y advanced chronic hepatitis C

@en

P2093

Anna S F Lok

http://www.w3.org/2001/XMLSchema#string

Chihiro Morishima

http://www.w3.org/2001/XMLSchema#string

HALT-C Trial Group

http://www.w3.org/2001/XMLSchema#string

Hae-Young Kim

http://www.w3.org/2001/XMLSchema#string

Herbert L Bonkovsky

http://www.w3.org/2001/XMLSchema#string

Jennifer L De Santo

http://www.w3.org/2001/XMLSchema#string

Karen L Lindsay

http://www.w3.org/2001/XMLSchema#string

Kristin K Snow

http://www.w3.org/2001/XMLSchema#string

Marc G Ghany

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

P2860

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.

P304

833-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23744

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Adrian M. Di Bisceglie

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44688912

http://www.w3.org/2001/XMLSchema#string

P698

20564351

http://www.w3.org/2001/XMLSchema#string

P921

P932

2932862

http://www.w3.org/2001/XMLSchema#string